Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Xlife Sciences AG's pretax income for the
six
months ended in Dec. 2025 was CHF-23.66 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-31.86 Mil.
Xlife Sciences AG's pretax margin was 29,944.30%.
During the past 8 years, Xlife Sciences AG's highest Pretax Margin was 6599.88%. The lowest was -11585.46%. And the median was 458.91%.
Xlife Sciences AG (XSWX:XLS) Pre-Tax Income Explanation
Xlife Sciences AG's Pretax Margin for the quarter that ended in Dec. 2025 is calculated as
During the past 8 years, Xlife Sciences AG's highest Pretax Margin was 6599.88%. The lowest was -11585.46%. And the median was 458.91%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG Pre-Tax Income Related Terms
Xlife Sciences AG Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:XLS vs VRTX, REGN, ALNY: Pre-Tax Income Comparison
For the Biotechnology subindustry, Xlife Sciences AG's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG Pre-Tax Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-31.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG (XSWX:XLS) has a Pre-Tax Income of CHF-31.86 Mil as of Dec. 2025. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Xlife Sciences AG and its competitors.
Is Xlife Sciences AG's Pre-Tax Income too high?
Xlife Sciences AG's current Pre-Tax Income is CHF-31.86 Mil. Overall, Xlife Sciences AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Pre-Tax Income compare to VRTX and REGN?
Xlife Sciences AG's Pre-Tax Income of CHF-31.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Pre-Tax Income is CHF-31.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.19, compared to a current price of CHF17.25 — trading 139.9% above its estimated fair value. The current Pre-Tax Income is CHF-31.86 Mil. Xlife Sciences AG's overall GF Score™ is 53/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Pre-Tax Income is CHF-31.86 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF17.25 is trading 139.9% above its estimated GF Value™ of CHF7.19.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
Pre-Tax Income: CHF-31.86 Mil
GF Value™: CHF7.19 vs. price of CHF17.25 (139.9% above fair value)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
53GF Score
Get the complete analysis for XSWX:XLS
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
